LAE-32
Chemical compound
From Wikipedia, the free encyclopedia
Lysergic acid ethylamide (LAE-32 or LAE), also known as N-ethyllysergamide, is a psychedelic drug of the lysergamide family related to lysergic acid diethylamide (LSD).[1][2][3] It is the analogue of LSD in which one of the ethyl groups on the amide moiety has been removed.[1][2]
- None
 | |
 | |
| Clinical data | |
|---|---|
| Other names | LAE32; LAE; LSE; Lysergic acid ethylamide; Lysergic acid monoethylamide; N-Ethyllysergamide; NE-LA; N-Ethylergine; N-Ethyl-LSA; N-Ethyl-6-methyl-9,10-didehydroergoline-8β-carboxamide |
| Routes of administration | Oral, intramuscular injection, subcutaneous injection[1] |
| Drug class | Serotonergic psychedelic; Hallucinogen |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C18H21N3O |
| Molar mass | 295.386 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
The drug is reported to have some LSD-like effects but is weaker and shorter-lasting, with an active dose reported to be between 0.5 and 1.6 mg by different routes of administration including subcutaneous or intramuscular injection and oral administration.[1][2][4] Side effects like apathy and sedation have been reported.[1]
Analogues of LAE-32 include LSD, MLA-74 (1-methyl-LAE), ALA-10 (1-acetyl-LAE; 1A-LAE), lysergic acid methylamide (LAM), lysergic acid propylamide (LAP), LME-54 (lysergic acid methylethylamide), and LEP-57 (lysergic acid ethylpropylamide; EPLA), among others.[1][2]
LAE-32 was first described in the scientific literature by Albert Hofmann and colleagues by 1955.[5] It was studied by the CIA as part of Project MKULTRA. Documents published by the CIA under the Freedom of Information Act suggest it causes "a schizophrenia-like condition" but it allows people with schizophrenia to remain indifferent to their disorder.[citation needed] The drug has also been studied in psychedelic-assisted psychotherapy.[4] It is not a controlled substance in Canada as of 2025.[6]